Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 4, July-August, p. 497–504

Publication type: editorial article

Language: English

The Role of Vitamin D3 in Inflammatory Bowel Diseases

Agnieszka Kosmowska-Miśków1,

1 2nd Department and Clinic of Pediatrics, Gastroenterology and Nutrition of the Wroclaw Medical University, Poland

Abstract

Vitamin D3, combined with its nuclear receptor, regulates more than 900 genes, which is the reason why its effect is pleiotropic. Among other effects, it influences the immunological system. Its deficit may be one of the environmental factors taking part in the development of auto-immunological diseases. The studies reveal that, among others things, inflammatory bowel diseases occur in higher latitudes, with lower exposure to solar radiation and with decreased production of vitamin D3 in the skin. Patients with inflammatory bowel disease have vitamin D3 deficiency more frequently. The application of vitamin D3, especially among adults with inflammatory bowel diseases, positively influences bone turnover markers and mostly due to its influence on immunological processes, vitamin D3 may be useful in the treatment of the primary health condition. It is necessary to determine the dosage range, as well as the optimal level of vitamin D3 metabolite–25OHD3, where the immunosuppressant effect is the best, with no toxic effects. Studies of vitamin D3 analogues deprived of the hypercalcemic influence, but with other merits of the basic substance remaining intact, are particularly promising.

Key words

vitamin D3, inflammatory bowel disease.

References (52)

  1. Grant W: Epidemiology of disease risks in relation to vitamin D insufficiency. Prog Biophys Mol Biol 2006, 92, 65–79.
  2. Peterlik M, Cross HS: Vitamin D nad calcium insufficiency – related chronic diseases: molecular and cellular pathophysiology. Eur J Clin Nutr 2009, 63, 1377–1386.
  3. Narula N, Marshall JK: Management of inflammatory bowel disease with vitamin D: Beyond bone health. J Crohns Colitis 2012, 6, 397–404.
  4. Wang TT, Tavera-Mendosa LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, Bourdeau V, Konstorum A, Lallemat B, Zhang R, Mader S, White JH: large – scale In silico and microarray – based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005, 19, 2685–2695.
  5. Kamen DL, Tangpricha V: Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med 2010, 88, 441–450.
  6. Yu XP, Bellido T, Manolagas SC: Down – regulation of NF-ĸB protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1995, 92, 10990–10994.
  7. Szeles L, Keresztes G, Torocsik D, Balajthy Z, Krenacs L, Poliska S, Steinmeyer A, Zuegel U, Pruenster M, Rot A, Nagy L: 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenie dendritic cell phenotype. J Immunol 2009, 182, 2074–2083.
  8. Penna G, Roncari A, Amuchastegui S, Danel KC, Berti E, Colonna M, Adorini L: Expression of the inhibitory receptor IlT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005, 106, 3490–3497.
  9. Baeke F, van Etten E, Gysemans C, Overbergh L, Mathieu C: Vitamin D signaling In immune – mediated disorders: Evolving insights and therapeutic opportunities. Mol Aspects Med 2008, 29, 376–387.
  10. Stoffels K, Overbergh L, Giulietti A, Verlinden, Bouillon R, Mathieu C: Immune regulation of 25-hydroxyvitamin – D3 – 1α-hydroxylase in human monocytes. J Bone Miner res 2006, 21, 37–47.
  11. Eggert M, Kluter A, Zettl UK, Neeck G: Transcription factors in autoimmune diseases. Curr Pharm Des 2004, 10, 2787–2796.
  12. Veldman CM, Cantorna MT, DeLuca HF: Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys 2000, 374, 334–338.
  13. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE: Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007, 179, 1634–1647.
  14. Cantorna MT, Hayes CE, DeLuca HF: 1,25-dihydroxycholecalciferol inhibits the progression of arthritis In murine models of human arthritis. J Nutr 1998, 128, 68–72.
  15. Cantorna MT, Woodward WD, Hayes CE, DeLuca HF: 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-β1 and Il-4. J Immunol 1998, 160, 5314–5319.
  16. Cantorna MT, Munsick C, Bemiss C, Mhon BD: 1,25–dihydroxycholecalciferol pevents and ameliorates smptoms of experimental murine inflammatory bowel disease. J Nutr 2000, 130, 2648–2652.
  17. Sonneberg A: Occupational distribution of inflammatory bowel disase among German employees. Gut 1990, 31, 1037–1040.
  18. Harries AD, Brown R, Heatley RV, Williams LA, Woodhead S, Rhodes J: Vitamin D status in Crohn’s disease: association with nutrition and disease activity. Gut 1995, 26, 1197–1203.
  19. Pappa HM, Grand RJ, Gordon CM: report on the vitamin D status of adult and pediatric patient with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 2006, 12, 1162–1174.
  20. Gilman J, Shanahan F, Cashman KD: Determinants of vitamin D status In adult Crohn’s disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr 2006, 60, 889–896.
  21. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS: Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr 2002, 76, 1077–1081.
  22. Levin AD, Wadhera V, Leach ST, Woodhead HJ, Lemberg DA, Medoza-Cruz AC, Day AS: Vitamin D deficiency In children with inflammatory bowel disease. Dig Dis Sci 2011, 56, 830–836.
  23. Pappa HM, Gordon CM, Saslowsky TM, Zholudev A, Horr B, Shih MC, Grand RJ: Vitamin D status in children and young adults with inflammatory bowel disease. Peditrics 2006, 118, 1950–1961.
  24. Fu Y-TN, Chatur N, Cheong-Lee C, Salh B: Hypovitaminosis D In adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci 2012, 57, 2144–2148.
  25. Holick MF: To screen Or not to screen for 25-hydroxyvitamin D: that is the D-lemma. Standardy Med 2012, 9, 590–594.
  26. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS: Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998, 114, 902–911.
  27. El-Matary W, Sikora S, Spady D: Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci 2011, 56, 825–829.
  28. Leslie WD, Miller N, Rogala L, Bernstein CN: Vitamin D status and bone den sity in recently diagnosed inflammatory bowel disease: The Manitoba IBD Cohort Sudy. Am J Gastroenterol 2008, 103, 1451–1459.
  29. Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Viljakainen H, Makitie O: Impaired bone helath in inflammatory bowel disease: A case – control study In 80 pediatric patients. Calcif Tissue Int 2012, 91, 121–130.
  30. Krzesiek E, Iwańczak B: Estimation of the frequency of osteopenia and osteoporosis in inflammatory bowel disease in children. Gastroenterol Pol 2006, 13, 105–109.
  31. Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z: Infiximab therapy improves the bone metabolizm in fistulizing Crohn’s disease. Dig Dis 2006, 24, 201–206.
  32. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA: Effect of Crohn’s disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner res 2002, 17, 695–702.
  33. Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S: Inflammation is the main determinant of low bone mineral density In pediatric inflammatory bowel disease. Inflamm Bowel Dis 2007, 13, 416–423.
  34. Miheller P, Muzes G, Hritz I, Lakatos G, Pregun I, Lakatos PL, Herszenyi L, Tulassay Z: Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn’s disease patients. Inflamm Bowel Dis 2009, 15, 1656–1662.
  35. Simmons JD, Mullighan C, Welsh KI, Jewell DP: Vitamin D receptor gene polymorphism: association with Crohn’s disease susceptibility. Gut 2000, 47, 211–214.
  36. Peyrin-Biroulet L, Oussalah A, Bigard MA: Crohn’s disease: the hot hypothesis. Med Hypotheses 2009, 73, 94–96.
  37. Yu S, Bruce D, Froicu M, Weaver V, cant orna MT: Failure of T cell homing, reduced CD4/CD8αα intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. PNAS 2008, 105, 20834–20839.
  38. Froicu M, Cantorna MT: Vitamin D and vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunology 2007, 8, 5.
  39. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT: A crucial role of vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003, 17, 2386–2392.
  40. Daniel C, Radeke HH, Sartory NA, Zahn N, Zuegel U, Steimeyer A, Stein J: The new low calcemic vitamin D analog 22 – ene – 25 – oxa – vitamin D prominently ameliorates T helper cell type – mediated colitis in mice. J Pharmacol Exp Therap 2006, 319, 622–631.
  41. Laverny G, Penna G, Vetrano S, Correale C, Nebuloni M, Danese S, Adorini L: Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol letters 2010, 131, 49–58.
  42. Stio M, Martinesi M, Bruni S, Treves C, Mathieu C, Verstuyf A, d’Albasio G, Bagnoli S, Bonanomi AG: The vitamin D analogue TX 527 blocks NF-ĸB activation in peripheral blood mononuclear cells of patients with Crohn’s disease. J Steroid Biochem Mol Biol 2007, 103, 51–60.
  43. D’Ambrosio D, Cippitello M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P: Inhibition of Il-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-ĸB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998, 101, 252–262.
  44. Stio M, Treves C, Martinesi M, Bonanomi AG: Biochemical effects of KH 1060 and anti-TNF monoclonal antibody on human peripheral blood mononuclear cells. Int Immunopathol 2005, 5, 649– 659.
  45. Daniel C, Sartory N, Zahn N, Radeke HH, Stein JM: Immune modulatory treatment of trinitrobezene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. Pharmacol Exp Therap 2008, 324, 23–33.
  46. Strauch UG, Obermeier F, Grunwald N, Dunger N, Rath HC, Scholmerich J, Steinmeyer A, Zugel U, Herfarth HH: Calcitriol analog ZK191784 ameliorates acute and chronic dextran sodium sulfate – induced colitis by modulation of intestinal dendritic cell numbers and phenotype. World J Gastroenterol 2007, 13, 6529–6537.
  47. Jorgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, Bartels LE, Keisen J, Christensen LA, Dahlerup JF: Clinical trial: vitamin D3 treatment in Crohn’s disease – a randomised double – blind placebo – controlled study. Aliment Pharmacol Ther 2010, 32, 377–383.
  48. Nicholson I, Dalzell AM, El-Matary W: Vitamin D as a therapy for colitis; a systematic review. J Crohns Colitis 2012, 6, 405–411.
  49. Schwalfenberg GK, Genuis SJ, Hiltz MN: Addresing vitamin D deficiency in Canada: a public health innovation whose time has come. Public Health 2010, 124, 350–359.
  50. Pappa HM, Mitchell PD, Jiang H, Kassiff S, Filip-Dhima R, DiFabio D, Quinn N, Lawton RC, Varvaris M, Van Straaten S, Gordon CM: Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. J Clin Endocrinol Metab 2012, 97, 2134–2142.
  51. Dobrzańska A i Zespół Ekspertów: Polskie zalecenia dotyczące profilaktyki niedoborów witaminy D – 2009. Pol Merk lek 2010, XXVIII, 130–133.
  52. Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Cole DEC, Atkinson SA, Josse RG, Feldman S, Kline GA, Rosen C: Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010, 182, 610–618.
© Wroclaw Medical University